Indolin-2-one p38α inhibitors II: Lead optimisation

Area of Science:

• Medicinal Chemistry
• Pharmacology

Background:

• p38α kinase is a validated target in inflammatory diseases.
• Indolin-2-one derivatives have shown potential as p38α inhibitors.
• Metabolic instability and poor bioavailability can limit the therapeutic efficacy of drug candidates.

Purpose of the Study:

• To optimize a series of indolin-2-one compounds targeting p38α kinase.
• To improve metabolic stability and oral bioavailability of the inhibitors.
• To develop non-cytotoxic drug candidates for potential therapeutic applications.

Main Methods:

• Structure-based drug design was employed to identify metabolic 'hot spots'.
• Chemical modifications focused on increasing compound polarity and blocking metabolic pathways.
• In vitro assays were used to assess compound cytotoxicity and p38α inhibition.
• In vivo pharmacokinetic studies in rats were conducted to evaluate oral bioavailability.

Main Results:

• A series of indolin-2-one derivatives were successfully optimized.
• Blocking of a key metabolic site and increased polarity led to enhanced metabolic stability.
• The optimized compounds demonstrated reduced cytotoxicity.
• Significant improvements in oral bioavailability were observed in rat models.

Conclusions:

• The optimized indolin-2-one inhibitors represent promising drug candidates for p38α-mediated diseases.
• Addressing metabolic liabilities and enhancing polarity are effective strategies for improving drug-like properties.
• Further development of these compounds may lead to novel anti-inflammatory therapies.